IL1B and idiopathic pulmonary fibrosis: In the early stage of IPF (acute lung injury), Deg-AZM reduced the number of inflammatory cells in BALF and decreased the secretion of inflammatory cytokines, including IL-4, IL-1β and IFN-γ, which have been demonstrated to be increased in IPF patients [29,30].